Sequenom, Inc. Announces Participation At The 34th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 6, 2016 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the 34th Annual J.P. Morgan Healthcare Conference.

On Wednesday, January 13, 2016, Sequenom will hold investor meetings at the 34th Annual J.P. Morgan Healthcare Conference, to be held at the St. Francis Hotel in San Francisco, CA.  Investors wishing to schedule a meeting with Sequenom should contact their J.P. Morgan representative or the Sequenom contacts listed above.  The company's investor presentation will be given at 4 pm Pacific time that day by Dr. Dirk van den Boom, President and Chief Executive Officer, and will be webcast on the company's website, www.sequenom.com/investors, and available for 90 days at the following link:

http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19842

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit www.laboratories.sequenom.com and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene®, VisibiliT™ and Sequenom Laboratories™ are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequenom-inc-announces-participation-at-the-34th-annual-jp-morgan-healthcare-conference-300200506.html

SOURCE Sequenom, Inc.